Hendrikus C. R. Ariese

Hendrikus C. R. Ariese

Auto-generated profile, based on publicly available information

Hendrikus C. R. Ariese

Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2022 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
JDJohanna F. Dekkers
Johanna F. Dekkers
MAMaria Alieva
Maria Alieva
ACAstrid Cleven
Astrid Cleven
FKFarid Keramati
Farid Keramati
AWAmber K. L. Wezenaar
Amber K. L. Wezenaar
ARAnne C. Rios
Anne C. Rios
Extending the success of cellular immunotherapies against blood cancers to the realm of solid tumors will require improved in vitro models that reveal therapeutic modes of action at the molecular level. Here we describe a system, called BEHAV3D, developed to study the dynamic interactions of immune cells and patient cancer organoids by means of imaging and transcriptomics. We apply BEHAV3D to live-track >150,000 engineered T cells cultured with patient-derived, solid-tumor organoids, identifying a ‘super engager’ behavioral cluster comprising T cells with potent serial killing capacity. Among other T cell concepts we also study cancer metabolome-sensing engineered T cells (TEGs) and detect behavior-specific gene signatures that include a group of 27 genes with no previously described T cell function that are expressed by super engager killer TEGs. We further show that type I interferon can prime resistant organoids for TEG-mediated killing. BEHAV3D is a promising tool for the characterization of behavioral-phenotypic heterogeneity of cellular immunotherapies and may support the optimization of personalized solid-tumor-targeting cell therapies.

30 September 2022 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
RIRavian L. van Ineveld
Ravian L. van Ineveld
RCRaphaël Collot
Raphaël Collot
MRMario Barrera Román
Mario Barrera Román
APAnna Pagliaro
Anna Pagliaro
NBNils Bessler
Nils Bessler
ARAnne C. Rios
Anne C. Rios

5 January 2026 in Nature Cancer
Verified
Journal Article
Open access
PDF file
NBNils Bessler
Nils Bessler
AWAmber K. L. Wezenaar
Amber K. L. Wezenaar
HAHendrikus C. R. Ariese
Hendrikus C. R. Ariese
CHCelina Honhoff
Celina Honhoff
NDNoëlle Dommann
Noëlle Dommann
ARAnne C. Rios
Anne C. Rios
Diffuse midline glioma (DMG) is a highly aggressive and untreatable pediatric cancer primarily arising in the pontine brainstem region, necessitating the development of representative models for treatment advance. Here we developed an FGF4-driven human brainstem organoid model, which we used to genetically engineer H3.3K27M-altered DMG. We demonstrated that brainstem pontine glial specification is critical for DMG tumorigenesis, yielding infiltrative tumors that recapitulate patient-representative intratumoral heterogeneity. Prolonged GD2 chimeric antigen receptor (CAR) T cell treatment mirrored clinical outcomes and revealed extensive transcriptional heterogeneity, from which both potent effector and dysfunctional CAR T cell populations could be identified. Furthermore, incorporation of myeloid cells generated DMG-specific microglia that reduced treatment efficacy and revealed CAR T cell functional states most vulnerable to microglia-mediated immunosuppression. Thus, we present a representative DMG model offering a months-long experimental window in vitro, which we leveraged to delineate CAR T cell functionality and microglial impact, aiding therapy development for this devastating disease.

1 May 2021 in Translational Oncology
Verified
Journal Article
Open access
PWPriscilla Wander
Priscilla Wander
SASusan T.C.J.M. Arentsen-Peters
Susan T.C.J.M. Arentsen-Peters
SPSandra S. Pinhanҫos
Sandra S. Pinhanҫos
BKBianca Koopmans
Bianca Koopmans
MDM.EMmy M. Dolman
M.EMmy M. Dolman
RSRonald W. Stam
Ronald W. Stam
Pediatric MLL-rearranged acute myeloid leukemia (AML) has a generally unfavorable outcome, primarily due to relapse and drug resistance. To overcome these difficulties, new therapeutic agents are urgently needed. Yet, implementing novel drugs for clinical use is a time-consuming, laborious, costly and high-risk process. Therefore, we applied a drug-repositioning strategy by screening drug libraries, comprised of >4000 compounds that are mostly FDA-approved, in a high-throughput format on primary MLL-rearranged AML cells. Here we identified pyrvinium pamoate (pyrvinium) as a novel candidate drug effective against MLL-rearranged AML, eliminating all cell viability at <1000 nM. Additional screening of identified drug hits on non-leukemic bone marrow samples, resulted in a decrease in cell viability of ∼50% at 1000 nM pyrvinium, suggesting a therapeutic window for targeting leukemic cells specifically. Validation of pyrvinium on an extensive panel of AML cell lines and primary AML samples showed comparable viabilities as the drug screen data, with pyrvinium achieving IC50 values of <80 nM in these samples. Remarkably, pyrvinium also induced cell toxicity in primary MLL-AF10+ AML cells, an MLL-rearrangement associated with a poor outcome. While pyrvinium is able to inhibit the Wnt pathway in other diseases, this unlikely explains the efficacy we observed as β-catenin was not expressed in the AML cells tested. Rather, we show that pyrvinium co-localized with the mitochondrial stain in cells, and hence may act by inhibiting mitochondrial respiration. Overall, this study shows that pyrvinium is highly effective against MLL-rearranged AML in vitro, and therefore represents a novel potential candidate for further studies in MLL-rearranged AML.